|
MediciNova Closes $7.5 Million Private Stock Sale to Kissei Pharmaceutical Co …
MarketWatch (press release) MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, … |
View full post on asthma – Google News